Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
Biogen Idec doesn't have any insights (yet...).
Redirecting to this page
Note: The design you were just viewing was captured on a day in the past. The design of this page might have changed since then, and it might look different on different devices.